Company Encyclopedia
View More
name
Chipscreen
688321.SH
Shenzhen Chipscreen Biosciences Co., Ltd. engages in the research and development of original small molecule drugs. The company develops Chidamide, a subtype-selective histone deacetylase inhibitor for the treatment of peripheral T-cell lymphoma and advanced hormone receptor-positive breast cancer; Chiglitazar Sodium, a PPAR pan-agonist for the treatment of metabolic diseases; and Chiauranib, a triple-pathway tumor-targeting inhibitor. It is also developing CS23546, a small-molecule PD-L1 inhibitor; CS231295, a brain-penetrant Aurora B selective inhibitor; CS32582, a highly selective small-molecule allosteric inhibitor of tyrosine kinase 2; CS12088, a hepatitis B nucleocapsid assembly modulator; and CS12192 a highly selective JAK3 kinase inhibitor.
3.097 T
688321.SHMarket value -Rank by Market Cap -/-

Financial Score

20/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking101/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE0.44%D
    • Profit Margin0.86%C
    • Gross Margin88.07%A
  • Growth ScoreA
    • Revenue YoY29.68%A
    • Net Profit YoY110.35%A
    • Total Assets YoY8.84%B
    • Net Assets YoY0.77%C
  • Cash ScoreA
    • Cash Flow Margin11686.47%A
    • OCF YoY29.68%A
  • Operating ScoreD
    • Turnover0.24D
  • Debt ScoreC
    • Gearing Ratio54.42%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Shenzhen Chipscreen Biosciences Gets Clinical Trial Approval for Pancreatic Cancer Treatment

    Shenzhen Chipscreen Biosciences Gets Clinical Trial Approval for Pancreatic Cancer Treatment

    marketscreener·
    SH
    688321
    +1.22%
    marketscreener·
    SH
    688321
    +1.22%

    Chipscreen plans to repurchase shares for 10 million to 15 million yuan

    According to the announcement from Chipscreen, the company plans to repurchase shares worth between 10 million and 15 million yuan, with the repurchase price not exceeding 47.46 yuan per share, which will be used for the employee stock ownership plan or equity incentives

    Zhitong·
    SH
    688321
    +1.22%
    Zhitong·
    SH
    688321
    +1.22%

    Chipscreen: The net profit for the third quarter is 41.1753 million yuan

    Chipscreen announced that its revenue for the third quarter was 268 million yuan, a year-on-year increase of 49.51%; net profit was 41.1753 million yuan. Revenue for the first three quarters was 674 million yuan, a year-on-year increase of 40.12%; net profit was 70.7675 million yuan

    Zhitong·
    SH
    688321
    +1.22%
    Zhitong·
    SH
    688321
    +1.22%

    Chipscreen: Bio-Thera Solutions plans to reduce its holdings by no more than 3% of shares

    Chipscreen announced that Boao Bio plans to reduce its holdings by no more than 3% in the next 6 months due to strategic planning needs, totaling 12.2339 million shares. The reduction will be carried out through a combination of centralized bidding and block trading, with no more than 1% reduction every 90 days during the centralized bidding period and no more than 2% reduction every 90 days during the block trading period

    Zhitong·
    SH
    688321
    +1.22%
    Zhitong·
    SH
    688321
    +1.22%

    Chipscreen released its semi-annual performance, with a net profit attributable to the parent company of 29.59 million yuan, turning a profit compared to the same period last year

    According to the Zhitong Finance APP, Chipscreen disclosed its semi-annual report for 2025, showing that the company achieved revenue of 407 million yuan during the reporting period, a year-on-year increase of 34.56%; the net profit attributable to the parent company was 29.59 million yuan, turning from loss to profit year-on-year; the net profit excluding non-recurring gains and losses was 20.32 million yuan, also turning from loss to profit year-on-year; the basic earnings per share were 0.0726 yuan

    Zhitong·
    SH
    688321
    +1.22%
    Zhitong·
    SH
    688321
    +1.22%
    © 2025 Longbridge｜Disclaimer